SensUs

Sensus Healthcare and CellMark Medical Partner to Accelerate International Expansion and Growth for Innovative Oncology and Aesthetic Solutions

Retrieved on: 
Tuesday, July 10, 2018
Biosensors, SensUs, Orchid Cellmark

"CellMark Medical was formed to create a pathway for domestically successful, innovative medical technologies to expand from their home markets into emerging geographic locations around the world," said Oliver Moorhouse, Head of the Americas, CellMark Medical.

Key Points: 
  • "CellMark Medical was formed to create a pathway for domestically successful, innovative medical technologies to expand from their home markets into emerging geographic locations around the world," said Oliver Moorhouse, Head of the Americas, CellMark Medical.
  • Achieving inaugural solution commitments in international markets within six months of launching speaks volumes for the collaboration that we have developed with the Sensus management team."
  • The collaboration aims to facilitate timely access for patients all over the world to Sensus' extensive portfolio of aesthetic and dermatology solutions, including SRT and Sensus Laser Systems, as well as the Company's future oncology solutions.
  • "Sensus' collaboration with CellMark Medical offers a critical boost of support to Sensus' international business development, which is a key priority for the Company this year," added Rick Golin, Sensus Healthcare Executive Vice President of International Sales.

Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit

Retrieved on: 
Tuesday, June 12, 2018
RTT, SensUs, Keloid, Melanoma, Dermatology, Cancer, Skin cancer, Skin, Biology, Medicine

The Summit is being held at the Westin Grand Central Hotel.

Key Points: 
  • The Summit is being held at the Westin Grand Central Hotel.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Reports First Quarter Financial Results Featuring 37% Revenue Growth

Retrieved on: 
Thursday, May 3, 2018
Earnings before interest, taxes, depreciation, and amortization, Fundamental analysis, Private equity, Profit, SensUs, GAAP, Human behavior, Science

Financial Results for the Three Months Ended March 31, 2018

Key Points: 
  • Financial Results for the Three Months Ended March 31, 2018
    Revenues for the first quarter of 2018 increased 37% to $6.0 million, compared with $4.4 million for the first quarter of 2017.
  • Gross profit for the first quarter of 2018 was $3.9 million, or 66.2% of revenue, compared with $2.9 million, or 65.6% of revenue, for the first quarter of 2017.
  • Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of performance.
  • Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare.

Sensus Healthcare Appoints Rita Gable as Vice President of Sales - Oncology

Retrieved on: 
Tuesday, May 1, 2018
RTT, Oncology, Medicine, Biology, Medical physics, Radiobiology, Biosensors, SensUs, Melanoma, Cancer, Radiation therapy, Health

BOCA RATON, Fla., May 1, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today the appointment of Rita Gable as its Vice President of Sales Oncology, effective immediately.

Key Points: 
  • BOCA RATON, Fla., May 1, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today the appointment of Rita Gable as its Vice President of Sales Oncology, effective immediately.
  • Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales experience, specializing in the oncology market.
  • "As we are committed to building the best team possible to support these efforts, Rita is a natural choice for this role.
  • Given her deep industry knowledge and leadership experience, Rita will propel Sensus' oncology business forward and enable us to penetrate additional markets."

Sensus Healthcare to Host First Quarter 2018 Financial Results and Business Update Conference Call on May 3, 2018

Retrieved on: 
Thursday, April 26, 2018
RTT, SensUs, Keloid, Skin cancer, Melanoma, Dermatology, Cancer, Toll-free telephone number, Skin, Biology, Integumentary system

In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Key Points: 
  • In addition, management will provide a business update and a discussion on recent and upcoming milestones.
  • To access the conference call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International), and 855-669-9657 (Canada Toll Free).
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Appoints Dr. Isabelle Raymond as Vice President, Clinical Development

Retrieved on: 
Tuesday, May 8, 2018
RTT, Skin cancer, Melanoma, Keloid, SensUs, Cancer, Dermatology, Skin, Biology, Integumentary system

BOCA RATON, Fla., May 8, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced the appointment of Dr. Isabelle Raymond, PhD, as Vice President, Clinical Development.

Key Points: 
  • BOCA RATON, Fla., May 8, 2018 /PRNewswire/ --Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced the appointment of Dr. Isabelle Raymond, PhD, as Vice President, Clinical Development.
  • Dr. Raymond, who will report to Joe Sardano, Sensus CEO, brings 14 years of medical device and pharmaceutical industry experience to the Company.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.

Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments

Retrieved on: 
Thursday, April 19, 2018
RTT, SensUs, Melanoma, Keloid, Cancer, Dermatology, Skin cancer, Skin, Biology, Integumentary system

Rick Golin, Executive Vice President of Oncology and International Sales, will spearhead this expansion, overseeing all international distributors.

Key Points: 
  • Rick Golin, Executive Vice President of Oncology and International Sales, will spearhead this expansion, overseeing all international distributors.
  • "Given the simultaneous growth of Sensus' geographic footprint and product offerings, we're in a perfect position to meet this demand.
  • Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids.
  • Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.